Anthracycline-induced chronic cardiotoxicity and heart failure

References

• Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13: 699–709
   PubMed Web of Science ®Google Scholar
• Von Hoff, DD, Layard, MW, Basa, P, Davis, HL, Jr, Von Hoff, AL, Rozencweig, M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710–7.
   PubMed Web of Science ®Google Scholar
• Xu MF, Tang PL, Qian ZM, Ashraf M. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci 2001; 68: 889–901
   PubMed Web of Science ®Google Scholar
• Escriba PV, Sastre M, Garcia-Sevilla JA. Disruption of cellular signaling pathways by daunomycin through destabilization of nonlamellar membrane structures. Proc Natl Acad Sci USA 1995; 92: 7595–9
   PubMedGoogle Scholar
• Kapelko VI, Williams CP, Gutstein DE, Morgan JP. Abnormal myocardial calcium handling in the early stage of adriamycin cardiomyopathy. Arch Physiol Biochem 1996; 104: 185–91
   PubMed Web of Science ®Google Scholar
• Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res 2001; 61: 771–7
   PubMed Web of Science ®Google Scholar
• Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics. J Mol Cell Cardiol 2006; 41: 389–405
   PubMed Web of Science ®Google Scholar
• Gianni L, Dombernowsky P, Sledge G, Martin M, Amadori D, Arbuck SG, et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer. Ann Oncol 2001; 12: 1067–73
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H, Koh E. Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: In vivo study. Circulation 2000; 102: 572–8
   PubMed Web of Science ®Google Scholar
• Torti FM, Bristow MM, Lum BL, Carter SK, Howes AE, Aston DA, et al. Cardiotoxicity of epirubicin and doxorubicin: Assessment by endomyocardial biopsy. Cancer Res 1986; 46: 3722–7
   PubMed Web of Science ®Google Scholar
• Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998; 16: 3502–8
   PubMed Web of Science ®Google Scholar
• Pichon MF, Cvitkovic F, Hacene K, Delaunay J, Lokiec F, Collignon MA, et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo 2005; 19: 567–76
   PubMed Web of Science ®Google Scholar
• Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749–54
   PubMed Web of Science ®Google Scholar
• Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 1992; 89: 942–9
   PubMed Web of Science ®Google Scholar
• Ritchie JL, Bateman TM, Bonow RO, Crawford MH, Gibbons RJ, Hall RJ, et al. Guidelines for clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology. J Am Coll Cardiol 1995; 25: 521–47
   PubMedGoogle Scholar
• Dorup I, Levitt G, Sullivan I, Sorensen K. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: The role of diastolic function. Heart 2004; 90: 1214–6
   PubMed Web of Science ®Google Scholar
• Robert J. Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs 1993; 45(Suppl 2)20–30
   PubMedGoogle Scholar
• Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185–229
   PubMed Web of Science ®Google Scholar
• O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440–9
   PubMed Web of Science ®Google Scholar
• van Dalen, EC, Michiels, EM, Caron, HN, Kremer, LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2006; CD005006.
   Google Scholar
• van Dalen, EC, van der Pal, HJ, Caron, HN, Kremer, LC. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2006; CD005008.
   Google Scholar
• van Dalen, EC, Caron, HN, Dickinson, HO, Kremer, LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2005; CD003917.
   PubMedGoogle Scholar
• Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17: 3333–55
   PubMed Web of Science ®Google Scholar
• Silber JH. Role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatr Blood Cancer 2005; 44: 607–13
   PubMed Web of Science ®Google Scholar
• Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115–40
   PubMed Web of Science ®Google Scholar
• Tallaj JA, Franco V, Rayburn BK, Pinderski L, Benza RL, Pamboukian S, et al. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 2005; 24: 2196–201
   PubMed Web of Science ®Google Scholar